Market Research Logo

Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015

Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2015’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Adenocarcinoma of the Gastroesophageal Junction Overview
Therapeutics Development
Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction - Overview
Adenocarcinoma of the Gastroesophageal Junction - Therapeutics under Development by Companies
Adenocarcinoma of the Gastroesophageal Junction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Adenocarcinoma of the Gastroesophageal Junction - Products under Development by Companies
Adenocarcinoma of the Gastroesophageal Junction - Companies Involved in Therapeutics Development
AB Science SA
Amgen Inc.
ArQule, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Gilead Sciences, Inc.
Imugene Limited
Johnson & Johnson
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Otsuka Holdings Co., Ltd.
Panacea Biotec Limited
Sanofi
Adenocarcinoma of the Gastroesophageal Junction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tipiracil hydrochloride + trifluridine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-337 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-853520 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRLX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DS-8201a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erismodegib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-5745 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Her-VAXX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMAB-362 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indusatumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipilimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBP-426 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solitomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tivantinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trastuzumab emtansine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenocarcinoma of the Gastroesophageal Junction - Recent Pipeline Updates
Adenocarcinoma of the Gastroesophageal Junction - Dormant Projects
Adenocarcinoma of the Gastroesophageal Junction - Discontinued Products
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones
Featured News & Press Releases
Jul 01, 2015: Phase 1b/2 Gastric Cancer Trial on Track with Contract Research Organisation Appointed to Conduct Trial
Jun 01, 2015: Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitor BBI608 in Multiple Cancer Types
May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting
Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Development by Companies, H2 2015 (Contd...2)
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Johnson & Johnson, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd...1), H2 2015
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report